Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco A Alba

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
RMD Open|January 5, 2018
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patientsSergio Prieto-González, Nekane Terrades-García, Marc Corbera-Bellalta, et al.
Annals of the Rheumatic Diseases|December 25, 2015
Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritisMarc Corbera-Bellalta, Ester Planas-Rigol, Ester Lozano, et al.
Journal of Internal Medicine|March 11, 2024
Significance of clinical-immunological patterns and diagnostic yield of biopsies in microscopic polyangiitis and granulomatosis with polyangiitisJoão Fernandes-Serodio, Sergio Prieto-González, Georgina Espígol-Frigolé, et al.
Seminars in Arthritis and Rheumatism|July 13, 2021
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain setJoanna Tieu, Jonathan Tl Cheah, Rachel J Black, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
RMD Open|January 5, 2018
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patientsSergio Prieto-González, Nekane Terrades-García, Marc Corbera-Bellalta, et al.
Annals of the Rheumatic Diseases|December 25, 2015
Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritisMarc Corbera-Bellalta, Ester Planas-Rigol, Ester Lozano, et al.
Journal of Internal Medicine|March 11, 2024
Significance of clinical-immunological patterns and diagnostic yield of biopsies in microscopic polyangiitis and granulomatosis with polyangiitisJoão Fernandes-Serodio, Sergio Prieto-González, Georgina Espígol-Frigolé, et al.
Seminars in Arthritis and Rheumatism|July 13, 2021
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain setJoanna Tieu, Jonathan Tl Cheah, Rachel J Black, et al.
Pageof 5